Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Khoury K, et al. Among authors: dang c. Breast Cancer Res Treat. 2021 Feb;185(3):863-868. doi: 10.1007/s10549-020-06053-y. Epub 2021 Jan 5. Breast Cancer Res Treat. 2021. PMID: 33400034 Free PMC article.
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Hurria A, et al. Among authors: dang c. Breast Cancer Res Treat. 2006 Aug;98(3):343-8. doi: 10.1007/s10549-006-9171-6. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541322
Cardiac dysfunction associated with trastuzumab.
Smith KL, Dang C, Seidman AD. Smith KL, et al. Among authors: dang c. Expert Opin Drug Saf. 2006 Sep;5(5):619-29. doi: 10.1517/14740338.5.5.619. Expert Opin Drug Saf. 2006. PMID: 16907652 Review.
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Traina TA, et al. Among authors: dang c. Breast Cancer Res Treat. 2008 Sep;111(2):377-88. doi: 10.1007/s10549-007-9787-1. Epub 2007 Oct 20. Breast Cancer Res Treat. 2008. PMID: 17952589 Clinical Trial.
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. Dang C, et al. J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733. J Clin Oncol. 2008. PMID: 18323546 Clinical Trial.
1,389 results